DB
DBV Technologies S.A.
DBV.PA · PAR
2.12 € +0.95% (+0.02 €)
1M -18.29%
Market Cap $413.6M
P/E Ratio -
Div. Yield -
ROE 119.47%
Bulios Fair Price
1.9 €
10.3% downside
Current Price
2.12 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DBV.PA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
37 /100
Fair P/S 72.15x
P/B 2.58x
P/E N/A
Growth
2 /100
Declining Book val. growth 4.62%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 122.19%
Net margin 3,074.92%
Op. margin 3,166.43%
Quality
0 /100
Poor ROIC 97.24%
ROE 119.47%
ROA 78.97%
Debt
100 /100
Low Debt/Equity 0.14x
Current ratio 3.72x
Int. coverage N/A
Stability
23 /100
Unstable Beta -0.21x
Rev. volatility 182.04%
EPS volatility 54.75%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DBV.PA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel Tassé
Employees
170
Headquarters
Châtillon
Upcoming events
28 OCT
Earnings
Upcoming earnings report